NEW YORK (GenomeWeb News) – MDx Health and HistoGeneX today announced a collaboration to provide molecular diagnostic testing services to drug manufacturers and oncologists.
Under the terms of the deal, MDxHealth will combine its epigenetics technologies with HistoGeneX's pharmacodiagnostic services. HistoGeneX's laboratory in Belgium will also provide MGMT methylation service testing for MDxHealth's clients.
MDxHealth's PharmacoMDx services use next-generation sequencing and deep sequencing technology for the discovery of epigenetics-based diagnostic and personalized therapeutic products.
"The collaboration with HistoGeneX further broadens our PharmacoMDx services on a global basis and expands upon our biomarker discovery program at the Center of Pharmaco (epi)Genomics, a joint-venture with Ghent University," MDx CEO Jan Groen said in a statement. "HistoGeneX has established a strong reputation in the pharma industry, [and] combining their Belgium-based CLIA certified laboratory services and expansive test menu with our US-based CLIA laboratory and next-gen epigenetic capabilities will enable both organizations to leverage our respective networks and grow our customer base."
HistoGeneX offers histology, pathology, and molecular diagnostic services for pharmaceutical and hospital customers.
Financial and other terms were not disclosed.